<p>2025 年 11 月 25 日- 上午 09:15</p>
<p>拉斯维加斯 --（商业资讯）--PharmaCyte Biotech, Inc.（纳斯达克：PMCB）（“PharmaCyte” 或 “公司”）今天宣布成功变现其在 Femasys Inc.（纳斯达克：FEMY）中的股份，进一步验证了公司在资本部署方面的战略方法，并加强了其已经稳固的财务状况。</p>
<p>在变现股份后，PharmaCyte 的现金和可交易证券预计将增加至约 2000 万美元，较 2025 年 7 月 31 日的 1330 万美元有所上升。这笔交易突显了公司识别和执行高质量机会的能力，这些机会能够带来强劲回报，同时保持保守的风险特征。</p>
<p>“我们成功变现 Femasys 的股份展示了我们战略性和有纪律的资本配置方法的有效性，” PharmaCyte 首席执行官 Josh Silverman 表示。“我们致力于智能地部署股东资本，平衡短期回报与能够带来持续价值创造的机会。”</p>
<p>根据最近提交的 10Q 报告，PharmaCyte Biotech 的可交易证券约为 2500 万美元，此外还有大约 2000 万美元的现金，包括来自 Femasys 变现的收益。尽管财务状况得到加强，PharmaCyte 的股票目前以每股 0.65 美元的价格交易，流通股约为 680 万股。</p>
<p>PharmaCyte 计划继续追求增值投资机会和有纪律的运营管理，以进一步提升股东回报。</p>
<p><strong>关于 PharmaCyte Biotech, Inc.</strong></p>
<p>PharmaCyte Biotech, Inc.（纳斯达克：PMCB）是一家生物技术公司，专注于开发用于癌症、糖尿病和其他严重疾病的细胞疗法。同时，公司采用有纪律的投资策略，旨在加强其财务状况，并通过战略性现金部署最大化股东价值。</p>
<p><strong>安全港声明</strong></p>
<p>本新闻稿可能包含根据 1995 年《私人证券诉讼改革法》所定义的前瞻性陈述，表达了 PharmaCyte 管理层和董事会的当前信念和期望。本新闻稿中任何不描述历史事实的陈述均为前瞻性陈述，可能面临风险和不确定性，这些风险和不确定性可能导致实际结果、表现和成就与这些前瞻性陈述中讨论的内容有实质性差异。可能影响我们实际结果的因素包括我们是否能够令人满意地解决 FDA 提出的问题，以便解除我们 IND 的临床暂停，是否成功探索创造新路径以实现股东价值的其他机会，以及我们向美国证券交易委员会提交的 10-K 和 10-Q 定期报告中包含的其他因素。这些前瞻性陈述仅在本日期作出，我们不承担更新或修订前瞻性陈述的义务，除非法律另有要求，无论是由于新信息、未来事件还是其他原因。有关 PharmaCyte Biotech 的更多信息，请访问 https://pharmacyte.com。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMjU3OTU5NTByMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMjU3OTU5NTByMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251125795950/en/</p>
<p>投资者联系：</p>
<p>CORE IR</p>
<p>ir@pharmacyte.com</p>
<p>媒体联系：</p>
<p>CORE IR</p>
<p>电子邮件：pr@coreir.com</p>
<p>来源：PharmaCyte Biotech, Inc.</p>

FEMY

PMCB

<p>PharmaCyte Biotech 成功变现其在 Femasys Inc. 的股份，使其现金和可交易证券增至 2000 万美元。这一举措凸显了 PharmaCyte 在资本部署方面的战略以及对提升股东价值的承诺。尽管财务状况得到加强，PharmaCyte 的股票仍以每股 0.65 美元交易。公司计划继续追求增值投资和严格管理，以进一步提升回报</p>

<p>11/25/2025 - 09:15 AM</p>
<div class="lb-trans"><p>2025 年 11 月 25 日- 上午 09:15</p>
</div><p>LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ: FEMY), further validating the Company’s strategic approach to capital deployment and strengthening its already solid financial position.</p>
<div class="lb-trans"><p>拉斯维加斯 --（商业资讯）--PharmaCyte Biotech, Inc.（纳斯达克：PMCB）（“PharmaCyte” 或 “公司”）今天宣布成功变现其在 Femasys Inc.（纳斯达克：FEMY）中的股份，进一步验证了公司在资本部署方面的战略方法，并加强了其已经稳固的财务状况。</p>
</div><p>Following the monetization of the stake, PharmaCyte’s cash and marketable securities are expected to increase to approximately $20 million, up from $13.3 million as of July 31, 2025. This transaction highlights the Company’s ability to identify and execute on high-quality opportunities that deliver strong returns while maintaining a conservative risk profile.</p>
<div class="lb-trans"><p>在变现股份后，PharmaCyte 的现金和可交易证券预计将增加至约 2000 万美元，较 2025 年 7 月 31 日的 1330 万美元有所上升。这笔交易突显了公司识别和执行高质量机会的能力，这些机会能够带来强劲回报，同时保持保守的风险特征。</p>
</div><p>“Our successful monetization of the Femasys position demonstrates the effectiveness of our strategic and disciplined capital allocation approach,” said Josh Silverman, PharmaCyte Chief Executive Officer. “We are committed to deploying shareholder capital intelligently, balancing near-term returns with opportunities that can deliver sustained value creation.”</p>
<div class="lb-trans"><p>“我们成功变现 Femasys 的股份展示了我们战略性和有纪律的资本配置方法的有效性，” PharmaCyte 首席执行官 Josh Silverman 表示。“我们致力于智能地部署股东资本，平衡短期回报与能够带来持续价值创造的机会。”</p>
</div><p>As valued in the most recently filed 10Q, PharmaCyte Biotech has approximately $25 million in marketable securities, in addition to roughly $20 million in cash, inclusive of the proceeds from the Femasys monetization. Despite this strengthened financial position, PharmaCyte’s stock currently trades at a recent price of $0.65 per share, with approximately 6.8 million shares outstanding.</p>
<div class="lb-trans"><p>根据最近提交的 10Q 报告，PharmaCyte Biotech 的可交易证券约为 2500 万美元，此外还有大约 2000 万美元的现金，包括来自 Femasys 变现的收益。尽管财务状况得到加强，PharmaCyte 的股票目前以每股 0.65 美元的价格交易，流通股约为 680 万股。</p>
</div><p>PharmaCyte plans to continue pursuing value-accretive investment opportunities and disciplined operational management to further enhance shareholder returns.</p>
<div class="lb-trans"><p>PharmaCyte 计划继续追求增值投资机会和有纪律的运营管理，以进一步提升股东回报。</p>
</div><p><strong>About PharmaCyte Biotech, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 PharmaCyte Biotech, Inc.</strong></p>
</div><p>PharmaCyte Biotech, Inc. (NASDAQ: PMCB) is a biotechnology company focused on developing cellular therapies for cancer, diabetes, and other serious diseases. In parallel, the Company employs a disciplined investment strategy designed to strengthen its financial position and maximize shareholder value through strategic cash deployment.</p>
<div class="lb-trans"><p>PharmaCyte Biotech, Inc.（纳斯达克：PMCB）是一家生物技术公司，专注于开发用于癌症、糖尿病和其他严重疾病的细胞疗法。同时，公司采用有纪律的投资策略，旨在加强其财务状况，并通过战略性现金部署最大化股东价值。</p>
</div><p><strong>Safe Harbor</strong></p>
<div class="lb-trans"><p><strong>安全港声明</strong></p>
</div><p>This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of PharmaCyte’s management and Board of Directors. Any statements contained in this press release which do not describe historical facts are forward-looking statements subject to risks and uncertainties that could cause actual results, performance, and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to satisfactorily address the issues raised by the FDA in order to have the clinical hold on our IND removed, whether our exploration of additional opportunities to create new paths toward shareholder value is successful, as well as such other factors that are included in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise. More information about PharmaCyte Biotech can be found at https://pharmacyte.com.</p>
<div class="lb-trans"><p>本新闻稿可能包含根据 1995 年《私人证券诉讼改革法》所定义的前瞻性陈述，表达了 PharmaCyte 管理层和董事会的当前信念和期望。本新闻稿中任何不描述历史事实的陈述均为前瞻性陈述，可能面临风险和不确定性，这些风险和不确定性可能导致实际结果、表现和成就与这些前瞻性陈述中讨论的内容有实质性差异。可能影响我们实际结果的因素包括我们是否能够令人满意地解决 FDA 提出的问题，以便解除我们 IND 的临床暂停，是否成功探索创造新路径以实现股东价值的其他机会，以及我们向美国证券交易委员会提交的 10-K 和 10-Q 定期报告中包含的其他因素。这些前瞻性陈述仅在本日期作出，我们不承担更新或修订前瞻性陈述的义务，除非法律另有要求，无论是由于新信息、未来事件还是其他原因。有关 PharmaCyte Biotech 的更多信息，请访问 https://pharmacyte.com。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMjU3OTU5NTByMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251125795950r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251125795950/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251125795950/en/</p>
</div><p>Investor Contact:</p>
<div class="lb-trans"><p>投资者联系：</p>
</div><p>CORE IR</p>
<div class="lb-trans"><p>CORE IR</p>
</div><p>ir@pharmacyte.com</p>
<div class="lb-trans"><p>ir@pharmacyte.com</p>
</div><p>Media Contact:</p>
<div class="lb-trans"><p>媒体联系：</p>
</div><p>CORE IR</p>
<div class="lb-trans"><p>CORE IR</p>
</div><p>Email: pr@coreir.com</p>
<div class="lb-trans"><p>电子邮件：pr@coreir.com</p>
</div><p>Source: PharmaCyte Biotech, Inc.</p>
<div class="lb-trans"><p>来源：PharmaCyte Biotech, Inc.</p>
</div>

PharmaCyte Biotech 成功变现其在 Femasys 的股份，增强了现金状况，并突显其战略资本部署 | FEMY 股票新闻